triazolam has been researched along with Neonatal Abstinence Syndrome in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Neonatal Abstinence Syndrome: Fetal and neonatal addiction and withdrawal as a result of the mother's dependence on drugs during pregnancy. Withdrawal or abstinence symptoms develop shortly after birth. Symptoms exhibited are loud, high-pitched crying, sweating, yawning and gastrointestinal disturbances.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attallah, A | 1 |
| Seilanian, M | 1 |
| Bavoux, F | 1 |
| Choisy, H | 1 |
1 other study available for triazolam and Neonatal Abstinence Syndrome
| Article | Year |
|---|---|
[Psychotropics and pregnancy. Apropos of 2 case reports: the dose of triazolam].
Topics: Apnea; Female; Half-Life; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Pregnancy; Pr | 1989 |